TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01616524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (pegIFNα-2a)
Description: Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 400 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 400 mg, Twice daily, 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 400 mg, Twice daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, Oral, 60 mg, Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Daclatasvir
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Daclatasvir
Description: Tablets, Oral, 0 mg, Once daily, 12 weeks
Study: NCT02597894

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy of Prostate
Description: Undergo biopsy

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02500888

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery
Description: Only one radiation session of about 180 Gy in bilateral internal capsule.
Study: NCT02326961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution Device
Description: ADRCs Prepared using the Celution Device
Study: NCT00369174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03227952

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrotactile stimulation
Description: Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vibrotactile stimulation
Description: Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
Study: NCT02379026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Drink/Diet
Description: 1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
Study: NCT02354131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib versus Bevacizumab-Niraparib combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib versus Bevacizumab-Niraparib combo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03395691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The distal approach
Description: The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The proximal approach
Description: The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
Study: NCT03804463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial cancer radical surgery
Description: Take hysterectomy and bilateral adnexectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fertility-sparing surgery
Description: Take endometrectomy , preserve uterus and bilateral ovaries.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian preservation surgery
Description: Take hysterectomy,preserve bilateral ovaries.
Study: NCT02169024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expect With Me group prenatal care
Description: Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard individual prenatal care
Description: Standard of care- individual prenatal care
Study: NCT01988662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neovascular Age-related Macular Degeneration
Description: Blood measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neovascular Age-related Macular Degeneration
Description: Blood measurement
Study: NCT01997957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
Study: NCT01113008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning
Description: Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
Study: NCT01933438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sup-ER Protocol
Description: Early shoulder repositioning (Sup-ER Splint)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard treatment
Study: NCT01969396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonoBiopsy Catheter
Description: Catheter utilized in dual role: sonohysterography and endometrial biopsy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial biopsy catheter
Description: Endometrial sample obtained without the assistance of sonohysterography
Study: NCT02873065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esoprazole
Study: NCT03027856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magmaris
Description: Implantation of a sirolimus eluting bioresorbable magnesium stent
Study: NCT00634257

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Nine questionnaires taking about 40 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Nine questionnaires taking about 40 minutes to complete.
Study: NCT01714037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0932
Description: Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0932
Description: Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0932
Description: Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
Study: NCT02549625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow-derived Mononuclear Cells
Study: NCT02049827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participation in the study
Study: NCT02514694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO32731

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04446507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium
Description: 1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium
Description: 1 dose of 2mg and 4 mg Saroglitazar magnesium will be given to subjects on Day 1
Study: NCT01748136

Intervention type: DEVICE
Intervention: CT Scan with Spirometry
Description: During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
Study: NCT00338832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physically Ready for Invigorating Movement Every Day (PRIME)
Description: The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for Activity, Leisure Skills, and Socialization (PALSS)
Description: PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
Study: NCT01988532

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionnaire
Study: NCT02632279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) depletion
Description: TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
Study: NCT02326961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celution Device
Description: ADRCs Prepared using the Celution Device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive Placebo
Study: NCT02821182

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiotherapy
Description: In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated \>48h and \<96h.
Study: NCT01110954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD L 506
Description: Two different doses will be compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD L 506
Description: Two different doses will be compared
Study: NCT03936543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Position change
Description: Different position during central line catheterization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional position
Description: Conventional position during central line catheterization
Study: NCT01347450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa powder berverage, dark chocolate bar
Description: Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
Study: NCT02417974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: Fecal Microbiota Transplant (FMT)
Study: NCT02371109

Intervention type: OTHER
Intervention: selftaken versus clinically taken swabs
Study: NCT03023475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LigaSure endoscopic vessel harvesting
Description: The radial artery will be harvested endoscopically using the LigaSure system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLS2 endoscopic vessel harvesting
Description: The radial artery will be harvested endoscopically using the TLS2 system.
Study: NCT00318110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NST using MUD for metastatic renal cell carcinoma
Description: Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11
Study: NCT02287272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 pMDI
Description: 4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine plus CHF5993 pMDI
Description: Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
Study: NCT03880071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT+ACT
Description: - The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DBT
Description: The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)
Study: NCT00760578

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160 90 mg
Description: Once daily, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSDC-0160 220 mg
Description: Once daily, oral
Study: NCT01635413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo strength training classes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo tai chi classes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo stretching and relaxation classes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02322918

Intervention type: GENETIC
Intervention: Blood samples for whole genomic/transcriptomic sequencing
Description: Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
Study: NCT00004978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2)
Description: Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
Study: NCT01033266

Intervention type: DIAGNOSTIC_TEST
Intervention: CPET
Description: CPET will be done on patients with overlap syndrome before and after clinical CPAP treatment.
Study: NCT03985449

Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (text only)
Description: The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.

Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)
Description: The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.

Intervention type: OTHER
Group type: OTHER
Intervention: Uterine Fibroid Option Grid encounter patient decision aid (online)
Description: Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
Study: NCT04533698

Intervention type: OTHER
Intervention: Assessment of reason for resternotomy
Description: No intervention is performed. Reasons for resternotomy (coagulation, fluid balance and other) are retrospectively assessed.

Intervention type: OTHER
Intervention: Assessment of reason for avoidance of resternotomy
Description: No intervention is performed. Reasons for avoidance resternotomy (coagulation, fluid balance and other) are retrospectively assessed.
Study: NCT04371991

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test (serum samples) for biochemical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test (serum samples) for biochemical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test (serum samples) for biochemical examination

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood test (serum samples) for biochemical examination
Study: NCT03331419

Intervention type: BEHAVIORAL
Intervention: Exercise test
Description: 30 sec of knee squats followed by a six minute walk test repeated on consecutive days.

Intervention type: BEHAVIORAL
Intervention: Exercise test
Description: 30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
Study: NCT00107445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV
Study: NCT02064868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: 30 µg/kg/day IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care
Description: This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.